Marja K Puurunen1, Shih-Jen Hwang2, Chris J O'Donnell3, Geoffrey Tofler4, Andrew D Johnson5. 1. Framingham Heart Study of Boston University School of Medicine and NHLBI, Framingham, MA, USA. 2. Framingham Heart Study of Boston University School of Medicine and NHLBI, Framingham, MA, USA; Population Sciences Branch, Division of Intramural Research, NHLBI, NIH, Bethesda, MD, USA. 3. Framingham Heart Study of Boston University School of Medicine and NHLBI, Framingham, MA, USA; Population Sciences Branch, Division of Intramural Research, NHLBI, NIH, Bethesda, MD, USA; Cardiology Section, Department of Medicine, Boston Veteran's Administration Healthcare, Boston, MA, USA. 4. Department of Cardiology, Royal North Shore Hospital, University of Sydney, Australia. 5. Framingham Heart Study of Boston University School of Medicine and NHLBI, Framingham, MA, USA; Population Sciences Branch, Division of Intramural Research, NHLBI, NIH, Bethesda, MD, USA. Electronic address: johnsonad2@nhlbi.nih.gov.
Abstract
INTRODUCTION: The relationship of venous thromboembolism (VTE) with platelet reactivity is unclear. Platelet function plays a key role in arterial thrombosis. Evidence suggests antiplatelet agents also effects in reducing VTE. Our aim is to describe the role of baseline platelet function in development of VTE in the community-based Framingham Heart Study (FHS) cohort. MATERIALS AND METHODS: Participants in the Framingham Offspring cohort fifth examination and Omni cohort first examination were eligible. We used light transmission aggregometry to measure platelet aggregation in response to collagen and a range of ADP and epinephrine doses. The study population consisted of 2831 participants [average age 54.3years; 57% female]. RESULTS AND CONCLUSIONS: During a median follow-up of 20.4years, we observed 138 incident VTE events. In age-, sex- and cohort-adjusted analysis an increase in collagen lag time was associated with increased risk for incident VTE (HR 1.01 [1.00-1.02]; p=0.049). Increased maximal aggregation to low dose epinephrine (1.0μM) was associated with lower VTE risk (HR 0.84 [0.71-0.99]; p=0.042]). However, additional multivariable analyses attenuated the collagen-VTE and epinephrine-VTE associations to trends, primarily due to adjustment for baseline body mass index (BMI), a VTE risk factor and potential modifier of platelet function. Secondary analyses considering varying follow-up periods, cancer incidence and interim aspirin use did not dramatically affect the collagen and epinephrine trends observed. Baseline platelet aggregability was only weakly associated with incident VTE, and in a paradoxical direction, in a community-based population. Other markers of platelet function and hemostasis could prove to be more useful predictors. Published by Elsevier Ltd.
INTRODUCTION: The relationship of venous thromboembolism (VTE) with platelet reactivity is unclear. Platelet function plays a key role in arterial thrombosis. Evidence suggests antiplatelet agents also effects in reducing VTE. Our aim is to describe the role of baseline platelet function in development of VTE in the community-based Framingham Heart Study (FHS) cohort. MATERIALS AND METHODS:Participants in the Framingham Offspring cohort fifth examination and Omni cohort first examination were eligible. We used light transmission aggregometry to measure platelet aggregation in response to collagen and a range of ADP and epinephrine doses. The study population consisted of 2831 participants [average age 54.3years; 57% female]. RESULTS AND CONCLUSIONS: During a median follow-up of 20.4years, we observed 138 incident VTE events. In age-, sex- and cohort-adjusted analysis an increase in collagen lag time was associated with increased risk for incident VTE (HR 1.01 [1.00-1.02]; p=0.049). Increased maximal aggregation to low dose epinephrine (1.0μM) was associated with lower VTE risk (HR 0.84 [0.71-0.99]; p=0.042]). However, additional multivariable analyses attenuated the collagen-VTE and epinephrine-VTE associations to trends, primarily due to adjustment for baseline body mass index (BMI), a VTE risk factor and potential modifier of platelet function. Secondary analyses considering varying follow-up periods, cancer incidence and interim aspirin use did not dramatically affect the collagen and epinephrine trends observed. Baseline platelet aggregability was only weakly associated with incident VTE, and in a paradoxical direction, in a community-based population. Other markers of platelet function and hemostasis could prove to be more useful predictors. Published by Elsevier Ltd.
Entities:
Keywords:
Deep vein thrombosis; Platelet aggregation; Platelet function tests; Platelets; Pulmonary embolism; Venous thromboembolism
Authors: John E Rectenwald; Daniel D Myers; Angela E Hawley; Christopher Longo; Peter K Henke; Kenneth E Guire; Alvin H Schmaier; Thomas W Wakefield Journal: Thromb Haemost Date: 2005-12 Impact factor: 5.249
Authors: Greta Lee Splansky; Diane Corey; Qiong Yang; Larry D Atwood; L Adrienne Cupples; Emelia J Benjamin; Ralph B D'Agostino; Caroline S Fox; Martin G Larson; Joanne M Murabito; Christopher J O'Donnell; Ramachandran S Vasan; Philip A Wolf; Daniel Levy Journal: Am J Epidemiol Date: 2007-03-19 Impact factor: 4.897
Authors: Andrew D Johnson; Lisa R Yanek; Ming-Huei Chen; Nauder Faraday; Martin G Larson; Geoffrey Tofler; Shiow J Lin; Aldi T Kraja; Michael A Province; Qiong Yang; Diane M Becker; Christopher J O'Donnell; Lewis C Becker Journal: Nat Genet Date: 2010-06-06 Impact factor: 38.330
Authors: Florian Prüller; Oliver Leopold Milke; Lukasz Bis; Friedrich Fruhwald; Daniel Scherr; Philipp Eller; Sascha Pätzold; Siegfried Altmanninger-Sock; Peter Rainer; Jolanta Siller-Matula; Dirk von Lewinski Journal: Ann Intensive Care Date: 2018-02-21 Impact factor: 6.925
Authors: Marja K Puurunen; Shih-Jen Hwang; Martin G Larson; Ramachandran S Vasan; Christopher J O'Donnell; Geoffrey Tofler; Andrew D Johnson Journal: J Am Heart Assoc Date: 2018-03-03 Impact factor: 5.501
Authors: Abu Saleh Md Moin; Ahmed Al-Qaissi; Thozhukat Sathyapalan; Stephen L Atkin; Alexandra E Butler Journal: Front Endocrinol (Lausanne) Date: 2021-03-30 Impact factor: 5.555
Authors: H G de Haan; A van Hylckama Vlieg; L A Lotta; M M Gorski; P Bucciarelli; I Martinelli; T P Baglin; F Peyvandi; F R Rosendaal Journal: J Thromb Haemost Date: 2018-10-16 Impact factor: 5.824